Abstract 
In the past decade, it became clear that epigenetic changes, including
alternative splicing, play a major role in cancer development and
progression. The contribution of alternative splicing and splicing factors
that regulate this process to cancer development and progression has been
understudied. Recently multiple studies have revealed altered splicing
patterns in cancers and several splicing factors were found to contribute
to tumor development. Studies using high throughput genomic analysis
have identified mutations in components of the core splicing machinery
as well as in splicing factors in several cancers.
In this lecture I will present our recent findings on how oncogenic
splicing factors promote cancer development and the metastatic process
and our development of splicing modulatory molecules as anti-cancer
drugs.
Rotem Karni, Ph.D.
The Institute for Medical Research IsraelCanada.
The Hebrew University-Hadassah Medical School